Florida International University

FIU Digital Commons
Department of Biostatistics Faculty
Publications

Robert Stempel College of Public Health &
Social Work

1-1-2021

Prevalence and Inpatient Hospital Outcomes of MalignancyRelated Ascites in the United States
Venkataraghavan Ramamoorthy
University of Central Missouri

Muni Rubens
Baptist Health South Florida

Anshul Saxena
Baptist Health South Florida

Chintan Bhatt
Baptist Health South Florida

Sankalp Das
Baptist Health South Florida

See next page for additional authors
Follow this and additional works at: https://digitalcommons.fiu.edu/biostatistics_fac

Recommended Citation
Ramamoorthy, Venkataraghavan; Rubens, Muni; Saxena, Anshul; Bhatt, Chintan; Das, Sankalp; Appunni,
Sandeep; Veledar, Emir; McGranaghan, Peter; Shehadeh, Nancy; Viamonte-Ros, Ana; Linhares, Yuliya; Odia,
Yazmin; Kotecha, Rupesh; and Mehta, Minesh P., "Prevalence and Inpatient Hospital Outcomes of
Malignancy-Related Ascites in the United States" (2021). Department of Biostatistics Faculty
Publications. 72.
https://digitalcommons.fiu.edu/biostatistics_fac/72

This work is brought to you for free and open access by the Robert Stempel College of Public Health & Social Work
at FIU Digital Commons. It has been accepted for inclusion in Department of Biostatistics Faculty Publications by
an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

Authors
Venkataraghavan Ramamoorthy, Muni Rubens, Anshul Saxena, Chintan Bhatt, Sankalp Das, Sandeep
Appunni, Emir Veledar, Peter McGranaghan, Nancy Shehadeh, Ana Viamonte-Ros, Yuliya Linhares, Yazmin
Odia, Rupesh Kotecha, and Minesh P. Mehta

This article is available at FIU Digital Commons: https://digitalcommons.fiu.edu/biostatistics_fac/72

Original Article

Prevalence and Inpatient Hospital
Outcomes of Malignancy-Related
Ascites in the United States

American Journal of Hospice
& Palliative Medicine®
2021, Vol. 38(1) 47-53
ª The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1049909120928980
journals.sagepub.com/home/ajh

Venkataraghavan Ramamoorthy, PhD1, Muni Rubens, PhD2 ,
Anshul Saxena, PhD3,4, Chintan Bhatt, MD, MPH3, Sankalp Das, MPH3,
Sandeep Appunni, MD5, Emir Veledar, PhD3,4, Peter McGranaghan, MS2,
Nancy Shehadeh, PhD6, Ana Viamonte-Ros, MD3,4, Yuliya Linhares, MD2,
Yazmin Odia, MD2,4, Rupesh Kotecha, MD2,4, and Minesh P. Mehta, MD2,4

Abstract
Objective: Malignancy-related ascites (MRA) is the terminal stage of many advanced cancers, and the treatment is mainly
palliative. This study looked for epidemiology and inpatient hospital outcomes of patients with MRA in the United States using
a national database. Methods: The current study was a cross-sectional analysis of 2015 National Inpatient Sample data and
consisted of patients 18 years with MRA. Descriptive statistics were used for understanding demographics, clinical
characteristics, and MRA hospitalization costs. Multivariate regression models were used to identify predictors of length of
hospital stay and in-hospital mortality. Results: There were 123 410 MRA hospitalizations in 2015. The median length of stay
was 4.7 days (interquartile range [IQR]: 2.5-8.6 days), median cost of hospitalization was US$43 543 (IQR: US$23 485-US$82
248), and in-hospital mortality rate was 8.8% (n ¼ 10 855). Multivariate analyses showed that male sex, black race, and admission
to medium and large hospitals were associated with increased hospital length of stay. Factors associated with higher in-hospital
mortality rates included male sex; Asian or Pacific Islander race; beneficiaries of private insurance, Medicaid, and self-pay; patients
residing in large central and small metro counties; nonelective admission type; and rural and urban nonteaching hospitals.
Conclusions: Our study showed that many demographic, socioeconomic, health care, and geographic factors were
associated with hospital length of stay and in-hospital mortality and may suggest disparities in quality of care. These factors
could be targeted for preventing unplanned hospitalization, decreasing hospital length of stay, and lowering in-hospital mortality
for this population.
Keywords
malignancy-related ascites, epidemiology, length of stay, in-hospital mortality, cost, National Inpatient Sample

Introduction
Peritoneal carcinomatosis is a complication of many gastrointestinal and gynecological malignancies. A number of abdominal and pelvic cancers such as pancreatic, ovarian, uterine, and
colorectal; extra-abdominal cancers such as lung, breast, and
lymphomas are associated with peritoneal carcinomatosis.1
This condition leads to malignancy-related ascites (MRA),
which is accumulation of fluid in the peritoneal cavity due to
increased vascular permeability and obstruction of the lymphatic capillaries by malignant cells. Accompanying symptoms
include abdominal distention, nausea and vomiting, pain, anorexia, fatigue, difficulty in breathing, and disproportionate
weight gain due to fluid accumulation.2 In majority of the
patients, interventions such as chemotherapy are ineffective,
and treatments usually include palliative measures such as
dietary restrictions, diuretics, and regular and intermittent

large-volume paracenteses.3 Malignancy-related ascites carries
poor prognosis and survival rates.4 In addition, this condition
significantly worsens quality of life by increasing symptom
burden and hospitalizations.5
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Malignancy-related ascites is a rare condition found in 7%
of all ascites cases, and available data on the prevalence and
economic burden of this condition are scarce.6 Although there
are some studies evaluating the effects of clinical factors on
hospital length of hospital stay and in-hospital mortality among
a limited number of patients with MRA, detailed, large database, and epidemiological analyses are lacking, especially at
the national level.4,7,8 In this study, we tried to understand the
epidemiology and inpatient hospital outcomes of patients with
MRA in the United States using a national database.

Methods
Data Source and Study Design
For this study, we analyzed 2015 National Inpatient Sample
(NIS) data. National Inpatient Sample is sponsored by a
Federal-State-Industry partnership by the Agency of Healthcare Research and Quality (AHRQ) as a part of Healthcare
Cost and Utilization Project.9 National Inpatient Sample is a
nationally representative and largest all-payer database publicly available for research purposes. National Inpatient Sample
includes weighted data of more than 35 million hospitalizations
every year. National Inpatient Sample annually collects a 20%
stratified sample of all discharge data from US hospitals except
from rehabilitation and long-term facilities and acute-care hospitals. International Classification of Diseases, Ninth and
Tenth Revisions, Clinical Modification (ICD-9-CM and ICD10-CM) codes are used for structuring and categorizing NIS
data into clinically meaningful sections.

Study Population and Measures
For this study, we extracted a subset of NIS data including adult
patients 18 years, with MRA as a primary or secondary diagnosis, determined by ICD-9-CM (158.8, 158.9, 197.6, 789.51)
or ICD-10-CM (C481, C48, C786, R180) diagnosis codes.
Hence, the study sample includes patients with ascites admitted
for ascites as well as other reasons. Using Clinical Classifications Software (CCS) codes 11 to 44, we identified the type of
cancer in patients already having MRA diagnosis. The primary
outcome was prevalence of MRA hospitalization. The secondary outcomes were hospital length of stay, in-hospital mortality, and hospitalization cost.

Statistical Analysis
SAS version 9.4 (SAS Institute) with procedures specifically
created for complex survey data were used for the analyses.
Descriptive statistics were used to understand the demographics, clinical characteristics, and costs of MRA hospitalization and were expressed in terms of median, interquartile
range (IQR), and percentage. Multivariate regression models
were used to find the relationship between independent and
outcome variables (length of stay and in-hospital mortality).
Since the percentage of missing data was small, and data were
not missing completely on random, we used NOMCAR option
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during regression analysis. P < .05 was considered statistically
significant.

Results
Characteristics of the Patients
There were 35 769 942 weighted hospitalizations recoded in
the year 2015. Among them, 123 410 (0.35%) were identified
as MRA (Table 1). The median age of the sample was
63.2 years (IQR: 54.2-71.9 years), and 65.6% were females.
Majority of the sample were whites (67.4%), followed by
blacks (14.3%), Hispanic (10.2%), and Asian or Pacific Islanders (4.6%). Slightly less than half of the sample (48.1%) were
Medicare beneficiaries, followed by private insurance (35.0%)
and Medicaid (12.2%). Slightly more than three-fourths
(77.8%) of the admissions were nonelective. Majority of MRA
hospitalizations were in large (61.3%) as opposed to medium
(24.9%) or small hospitals (13.8%). When evaluated by hospital type, (rural, urban nonteaching, or urban teaching), urban
teaching hospitals had the largest proportion of patients with
MRA (76.9%). Evaluation by geographic regions revealed
almost similar distributions in Northeast (23.2%), Midwest
(22.2%), and West (20.5%), while the South being the exception had the largest proportion of MRA admissions (34.1%;
Table 1).

Common Cancer Types Among Patients With MRA
The most common primary malignancies were ovary (27.2%),
gastrointestinal organs and peritoneum (20.5%), colon
(11.7%), pancreas (6.4%), stomach (5.7%), uterus (5.2%), and
breast (3.7%). Among males, most common primary malignancies were gastrointestinal organs and peritoneum (6.6%), colon
(6.0%), pancreas (3.2%), male genital organs (3.1%), and stomach (3.0%). Among females, most common primary malignancies were ovary (27.2%), gastrointestinal organs and
peritoneum (13.9%), colon (5.7%), uterus (5.2%), breast
(3.7%), and pancreas (3.2%; Table 2).

Hospital Length of Stay, Mortality, and Cost
The median length of stay was 4.7 days (IQR: 2.5-8.6 days),
and median cost of hospitalization was $43 543 (IQR: $23 485$82 248; Table 3). This accounted for a total hospitalization
cost of $6.4 billion in 2015. The differences in median length of
stay and hospitalization costs by patient characteristics are
shown in Table 3. The overall in-hospital mortality rate was
8.8% (n ¼ 10 855), among males 10.8% (n ¼ 4600) and among
females 7.7% (n ¼ 6255). The mortality rates according to
patient characteristics are shown in Table 3.

Factors Associated With Length of Stay and Mortality
Multivariate analyses showed that factors such as male sex
(odds ratio [OR]: 1.06; 95% CI: 1.01-1.12), black race (OR:
1.18; 95% CI: 1.09-1.28), and admission to medium hospitals
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Table 1. Characteristics of the Patients Hospitalized with MalignancyRelated Ascites in the United States in 2015.a
Variable

Table 2. Primary Malignancy Types Among Patients Hospitalized with
Malignancy-Related Ascites.a

n (%)
Primary malignancy types

Unweighted sample
Weighted sample
Age, years, median (IQR)
Sex, n (%)
Male
Female
Race, n (%)
White
Black
Hispanic
Asian or Pacific Islander
Native American
Other
Primary payer, n (%)
Medicare
Medicaid
Private
Self-pay
No charge
Other
Location of patients’ residence, n (%)
Large central counties
Large fringe counties
Medium metro counties
Small metro counties
Micropolitan counties
Not metropolitan or micropolitan counties
Admission type, n (%)
Nonelective
Elective
Hospital region, n (%)
Northeast
Midwest
South
West
Hospital bed size, n (%)
Small
Medium
Large
Hospital type, n (%)
Rural
Urban nonteaching
Urban teaching

24 682 (100.0%)
123 410
63.2 (54.2-71.9)
42 415 (34.4%)
80 995 (65.6%)
78 640
16 745
11 875
5330
545
3610

(67.4%)
(14.3%)
(10.2%)
(4.6%)
(0.5%)
(3.1%)

59 315
15 080
43 170
2695
355
2700

(48.1%)
(12.2%)
(35.0%)
(2.2%)
(0.3%)
(2.2%)

40 910
33 100
22 710
10 155
9075
6860

(33.3%)
(27.0%)
(18.5%)
(8.3%)
(7.4%)
(5.6%)

95 580 (77.8%)
27 310 (22.2%)
28 680
27 380
42 065
25 285

(23.2%)
(22.2%)
(34.1%)
(20.5%)

17 080 (13.8%)
30 695 (24.9%)
75 635 (61.3%)
5585 (4.5%)
22 895 (18.6%)
94 930 (76.9%)

Abbreviation: IQR, interquartile range.
a
Elective admissions include nonemergency admissions, and nonelective
include admissions from the emergency department.

(OR: 1.24; 95% CI: 1.14-1.34) and large hospitals (OR: 1.31;
95% CI: 1.22-1.41) were associated with prolonged hospital
length of stay (Table 4). The top 3 malignancies associated
with longer hospital length of stay were hematologic malignancies (lymphoma and leukemia) and uterine and colon cancers (Table 4). Factors associated with shorter hospital length
of stay were being a private insurance beneficiary (OR: 0.88;
95% CI: 0.82-0.94), having self-paid insurance (OR: 0.82; 95%
CI: 0.69-0.98), being admitted to hospitals in the Midwest (OR:
0.89; 95% CI: 0.82-0.96), the west (OR: 0.83; 95% CI: 0.77-

Male, % (SE)

Female,
% (SE)

Total

Stomach
3.0% (0.33) 2.7% (0.31) 5.7% (0.45)
Colon
6.0% (0.46) 5.7% (0.45) 11.7% (0.62)
Liver
1.9% (0.27) 1.6% (0.24) 3.5% (0.36)
Pancreas
3.2% (0.35) 3.2% (0.34) 6.4% (0.48)
GI organs and peritoneum 6.6% (0.48) 13.9% (0.67) 20.5% (0.78)
Lung and bronchus
0.6% (0.15) 0.5% (0.13) 1.1% (0.20)
Breast
0.04% (0.04) 3.7% (0.37) 3.7% (0.37)
Uterus
5.2% (0.43) 5.2% (0.43)
Ovary
27.2% (0.86) 27.2% (0.86)
Other female genital
3.4% (0.35) 3.4% (0.35)
organs
Male genital organs
3.1% (0.34)
3.1% (0.34)
Melanomas of skin
1.8% (0.26) 1.3% (0.22) 3.1% (0.34)
Urinary
1.4% (0.23) 1.4% (0.22) 2.8% (0.32)
Lymphomas and leukemia
1.1% (0.21) 1.5% (0.23) 2.6% (0.31)
Abbreviations: GI, gastrointestinal; SE, standard error.
a
Cancer with unspecified primary, secondary malignancies, and malignant
neoplasm without specification of site were excluded from this analysis.

0.90), rural hospitals (OR: 0.64; 95% CI: 0.56-0.74), and urban
nonteaching hospitals (OR: 0.83; 95% CI: 0.78-0.89). Please
see Table 4 for reference categories.
Factors associated with higher in-hospital mortality rates
were being male (OR: 1.34; 95% CI: 1.22-1.48), belonging to
Asian or Pacific Islander race (OR: 1.29; 95% CI: 1.05-1.60),
being private insurance (OR: 1.29; 95% CI: 1.13-1.47) or Medicaid (OR: 1.23; 95% CI: 1.03-1.47) beneficiaries, having selfpaid insurance (OR: 1.60; 95% CI: 1.17-2.17), residing in large
central (OR: 1.18; 95% CI: 1.03-1.34) and small metro counties
(OR: 1.24; 95%; CI: 1.02-1.51), nonelective admission
type (OR: 2.40; 95% CI: 2.06-2.79), and being admitted to
rural (OR: 1.37; 95% CI: 1.06-1.78) and urban nonteaching
(OR: 1.16; 95% CI: 1.03-1.31) hospitals. The top 3 malignancies associated with higher in-hospital mortality were liver,
lung and bronchus, and secondary malignancies. Please see
Table 4 for reference categories.

Discussion
To the best of our knowledge, this is the first study that looked
for prevalence and inpatient burden of MRA hospitalization
using a national database. In the year 2015, there were 123
295 MRA hospitalizations, and total hospitalization cost was
nearly $6.4 billion.
In our study, MRA was most commonly seen in ovarian
cancer, followed by cancers of gastrointestinal organs and peritoneum, colon, pancreas, stomach, uterus, and breast. Other
studies have reported similar associations between MRA and
type of cancer; however, relative percentages and order of
frequencies were different.4,7 For example, in a retrospective
study of 209 patients with cancer, MRA was most commonly
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Table 3. Hospitalization Length, Charges, and Mortality for Malignancy-Related Ascites in the United States in 2015.
Variable
Entire cohort
Sex
Male
Female
Race
White
Black
Hispanic
Asian or Pacific Islander
Native American
Other
Primary payer
Medicare
Medicaid
Private
Self-pay
No charge
Other
Location of patients’ residence
Large central counties
Large fringe counties
Medium metro counties
Small metro counties
Micropolitan counties
Not metropolitan or micropolitan counties
Admission type
Nonelective
Elective
Hospital region
Northeast
Midwest
South
West
Hospital size
Small
Medium
Large
Hospital type
Rural
Urban nonteaching
Urban teaching

Length of stay in days,
median (IQR)

Total charge in us dollars,
median (IQR)

In-hospital mortality,
n (%)

4.7 (2.5-8.6)

43 543 (23 485-82 248)

10 855 (8.8%)

4.8 (2.5-8.9)
4.7 (2.4-8.5)

44 184 (23 673-84 971)
43 184 (23 335-80 796)

4600 (10.8%)
6255 (7.7%)

4.7 (2.4-8.4)
5.2 (2.6-9.7)
4.9 (2.4-8.8)
4.6 (2.5-8.7)
4.0 (2.1-8.5)
5.1 (2.5-9.1)

42
42
51
53
36
51

547 (23
736 (23
437 (27
458 (27
142 (22
551 (26

030-79 606)
196-80 962)
927-10 0552)
573-102 105)
904-69 520)
597-95 724)

6645 (8.4%)
1590 (9.5%)
975 (8.2%)
600 (11.3%)
65 (11.9%)
420 (11.6%)

4.9 (2.5-8.7)
4.9 (2.5-9.6)
4.6 (2.4-8.3)
4.5 (2.3-8.5)
4.7 (2.4-9.1)
4.2 (2.0-8.1)

43
45
44
39
39
37

034 (23
796 (23
150 (23
017 (22
860 (20
215 (16

595-81
870-90
658-82
760-73
678-72
758-73

224)
738)
538)
863)
696)
932)

5190 (8.8%)
1330 (8.8%)
3645 (8.4%)
300 (11.1%)
25 (7.0%)
340 (12.6%)

4.8 (2.4-8.8)
4.8 (2.5-8.5)
4.8 (2.5-8.6)
4.7 (2.5-8.4)
4.5 (2.5-8.2)
4.4 (2.3-8.7)

50
43
41
37
35
34

015 (27
977 (23
932 (22
239 (21
370 (18
757 (18

227-94
138-83
782-77
356-68
417-66
714-65

287)
883)
689)
399)
043)
919)

3945 (9.6%)
2720 (8.2%)
1770 (7.8%)
915 (9.0%)
840 (9.3%)
595 (8.7%)

4.7 (2.4-8.9)
4.8 (2.7-7.8)

40 485 (21 873-78 549)
54 600 (32 177-93 934)

9725 (10.1%)
1100 (4.0%)

4.9 (2.5-9.0)
4.6 (2.5-8.2)
4.9 (2.5-8.9)
4.4 (2.3-8.1)

46
37
39
56

2790 (9.7%)
2005 (7.3%)
3620 (8.6%)
2440 (9.7%)

4.3 (2.2-7.9)
4.7 (2.5-8.6)
4.9 (2.5-8.8)

35 923 (19 257-70 966)
41 962 (22 724-80 389)
45 955 (24 907-85 664)

1575 (9.2%)
2795 (9.1%)
6485 (8.6%)

3.8 (2.1-7.3)
4.5 (2.3-8.1)
4.8 (2.5-8.8)

23 805 (12 725-43 878)
42 555 (22 752-80 347)
45 268 (24 648-85 210)

660 (11.8%)
2290 (10.0%)
7905 (8.3%)

805 (24
496 (20
910 (21
873 (30

714-89 303)
881-67 184)
547-74 444)
593-107 652)

Abbreviation: IQR, interquartile range.

seen in ovarian (38%), pancreaticobiliary (21%), gastric (18%),
esophageal (4%), colorectal (4%), and breast (3%) cancer.4 The
greater proportion of female patients observed in our study was
also seen in another smaller study that reported 140 (67%)
females of 209 MRA hospitalizations.4 This could be because
common cancers among females are more likely to cause
ascites. For example, breast, uterine, and ovarian cancers,
which constitute the first, fourth, and tenth most common cancers among females are more commonly associated with MRA,
whereas prostate cancer, which is the most common cancer
among males, is not associated with MRA.10 For cancers that
are non-sex-specific such as lymphomas, leukemia, lung, and

gastrointestinal cancers, MRA rates were similar between
the sexes.
In our study, the median hospital length of stay for MRA
was 4.7 days. Patient-specific factors that were associated with
longer hospital length of stay were male sex, black race, and
admission to medium and large hospitals and may suggest
existing disparities in quality of care. In addition, some types
of cancers were also associated with longer hospital length of
stay. Many studies have discussed the effects of treatment
options on hospital length of stay among patients with
MRA.11-14 However, the effects of patient-specific variables
on hospital length of stay have not been adequately discussed,
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Table 4. The Effects of Selected Predictor Variables on Inpatient Mortality and Length of Stay.
Variable
Age
Sex
Male
Female
Race
White
Black
Hispanic
Asian or Pacific Islander
Native American
Other
Primary payer
Private
Medicare
Medicaid
Self-pay
No charge
Other
Location of patients’ residence
Large central counties
Large fringe counties
Medium metro counties
Small metro counties
Micropolitan counties
Not metropolitan or micropolitan counties
Admission type
Nonelective
Elective
Hospital region
Northeast
Midwest
South
West
Hospital size
Small
Medium
Large
Hospital type
Rural
Urban nonteaching
Urban teaching
Primary types of malignancies
Stomach
Colon
Liver
Pancreas
GI organs and peritoneum
Lung and bronchus
Breast
Uterus
Ovary
Other female genital organs
Male genital organs
Melanomas of skin
Urinary
Lymphomas and leukemia
Cancer with unspecified primary
Secondary malignancies
Malignant neoplasm without specification of site
a
b

Antilogarithms of b coefficient.
Significant values.

Length of stay, transformed coefficient (95% CI)a Died during hospitalization, OR (95% CI)
0.99 (0.98-1.00)

1.01 (1.00-1.02)

1.06 (1.01-1.12)b
Reference

1.34 (1.22-1.48)b
Reference

Reference
1.18 (1.09-1.28)b
1.04 (0.95-1.14)
1.08 (0.95-1.23)
1.01 (0.70-1.47)
1.09 (0.94-1.27)

Reference
1.12 (0.97-1.29)
0.93 (0.78-1.11)
1.29 (1.05-1.60)b
1.12 (0.58-2.16)
1.41 (1.11-1.80)b

0.88 (0.82-0.94)b
Reference
1.03 (0.93-1.13)
0.82 (0.69-0.98)b
0.86 (0.51-1.46)
0.72 (0.60-0.87)b

1.29 (1.13-1.47)b
Reference
1.23 (1.03-1.47)b
1.60 (1.17-2.17)b
0.99 (0.39-2.50)
1.75 (1.30-2.36)b

1.00 (0.93-1.07)
Reference
1.02 (0.94-1.10)
1.06 (0.95-1.17)
1.07 (0.94-1.20)
1.01 (0.88-1.15)

1.18 (1.03-1.34)b
Reference
0.95 (0.81-1.11)
1.24 (1.02-1.51)b
1.17 (0.92-1.49)
1.20 (0.94-1.55)

0.98 (0.92-1.03)
Reference

2.40 (2.06-2.79)b
Reference

Reference
0.89 (0.82-0.96)b
0.99 (0.92-1.06)
0.83 (0.77-0.90)b

Reference
0.71 (0.61-0.83)b
0.87 (0.76-0.98)b
0.92 (0.80-1.06)

Reference
1.24 (1.14-1.34)b
1.31 (1.22-1.41)b

Reference
0.98 (0.84-1.15)
0.92 (0.80-1.06)

0.64 (0.56-0.74)b
0.83 (0.78-0.89)b
Reference

1.37 (1.06-1.78)b
1.16 (1.03-1.31)b
Reference

1.49 (1.03-2.15)b
2.10 (1.63-2.70)b
1.04 (0.68-1.57)
1.10 (0.79-1.53)
1.21 (0.97-1.52)
1.40 (0.65-3.01)
0.79 (0.53-1.17)
1.94 (1.19-3.17)b
Reference
1.53 (1.02-2.30)b
0.93 (0.62-1.41)
1.45 (1.01-2.08)b
0.91 (0.68-1.39)
2.40 (1.52-3.79)b
1.15 (0.68-1.93)
1.66 (1.44-1.91)b
1.49 (1.26-1.77)b

2.09 (1.03-4.24)b
1.11 (0.55-2.25)
3.91 (1.92-7.93)b
2.32 (1.17-4.57)b
1.11 (0.60-2.04)
3.33 (1.93-4.73)b
0.95 (0.28-3.24)
1.87 (0.73-4.73)
Reference
0.71 (0.16-3.06)
0.87 (0.26-2.91)
2.36 (0.98-5.71)
1.87 (0.73-4.73)
1.96 (0.71-5.42)
0.44 (0.06-3.31)
2.35 (1.54-3.59)b
2.83 (1.81-4.44)b

52
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and our study is one of the first few to address this gap.
Malignancy-related ascites is a serious condition for which
treatment is primarily palliative, and hence treatment options
should be minimally invasive and hospital stay should be minimal.14,15 Studies have also shown that starting palliative care
early in the course of the treatment results in significant
improvement in symptom burden, survival rate, patient and
caregiver satisfaction, quality of life, and length of stay.16,17
In addition, targeting patient-specific factors and disparities
found in our study could additionally decrease hospital length
of stay in patients with MRA.
In our study, in-hospital mortality rates were 8.8%, suggesting a relatively higher short-term mortality among MRA hospitalization. In general, life expectancy ranges between 10 and
23 weeks after diagnosis of MRA and depends on several treatment and patient factors.4,8 However, our study looked for
deaths that occurred in hospital only and not after discharge.
Hence, we cannot not entirely compare our findings to previous
studies on survival characteristics in MRA. In our study, sex,
race, residence location, admission type, hospital region, and
hospital type were associated with in-hospital mortality rates,
again indicating disparities in quality of care. There are very
few studies that looked for predictors of in-hospital mortality
among patients with MRA.4,7 For example, Mackey et al
showed that liver metastasis, low serum albumin, and edema
were associated with higher in-hospital mortality, while ovarian cancer was associated with lower in-hospital mortality.18
Similarly, Garrison et al showed that patients with MRA having primary cancer of female genital organs had higher survival
rates, while those with foregut adenocarcinoma had lower survival rates.8 A study by Ayantunde et al showed that poor
performance status measured by Karnofsky index scoring system, cancer type, liver metastases, lower serum albumin, and
higher urea levels were associated with lower survival rates.7 In
addition to these predictors, our study provides many patient
specific factors that could affect in-hospital mortality.
We found that nearly 78% of MRA hospitalizations were
nonelective admissions. This finding appears to very high
given that MRA is a condition that could be managed in the
outpatient settings with facilities for ascetic fluid drainage.
This is likely reflective of the fact that very few medical centers
or facilities have outpatient clinics for routine ascites drainage,
forcing physicians to send patients with malignant ascites to the
emergency department and admit them to inpatient services.
This is additionally taxing to the health care system because
every MRA hospitalization incurs an average expenditure of
$44 000, accounting to a total of $6.4 billion nationally in 2015
alone. Our findings suggest that much of these expenditures
could be avoided by providing home hospice care, where
patients with MRA could managed by trained professionals
in the comfort of their homes.

given the rarity of this condition. This was possible because
NIS annually gathers nationally representative weighted data
from more than 35 million hospitalizations in the United States.
This relatively large sample size is useful for conducting multivariate analyses and understanding the variables that predicted
the outcomes. National Inpatient Sample is a nationally representative sample, and results of our study could be considered
MRA estimates for the entire United States. Despite these
strengths, there were some limitations. The ICD-9-CM, ICD10-CM, and CCS codes were used to identify MRA and different types of primary cancers. Despite the specificity of these
codes, there could be some coding errors leading to misclassification biases. National Inpatient Sample does not have data
on clinical settings, imaging tests, or ascitic fluid analyses to
independently confirm MRA diagnosis. In addition, NIS does
not have follow-up data and discharge destination, and hence
we could not understand disease course and survival characteristics in this population. National Inpatient Sample excludes
personal identifiers for confidentiality. Because of this, we
were not able to differentiate between first and subsequent
hospitalization. Patients who were readmitted were considered
as independent new admissions, thus obliterating the difference
between index case and readmitted case. This could have overestimated MRA hospitalization in our study. Finally, NIS does
not record the cause of death and this limited us from understanding whether all in-hospital deaths in MRA hospitalization
are attributable to this condition.

Strengths and Limitations
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